FR2318646A1 - Intravenous or perfusion anaesthetic - contg. a soln. of hydroxy pregnane dione in (2,2)-dimethyl-(4)-hydroxy-methyl-(1,3)-dioxolane - Google Patents

Intravenous or perfusion anaesthetic - contg. a soln. of hydroxy pregnane dione in (2,2)-dimethyl-(4)-hydroxy-methyl-(1,3)-dioxolane

Info

Publication number
FR2318646A1
FR2318646A1 FR7523269A FR7523269A FR2318646A1 FR 2318646 A1 FR2318646 A1 FR 2318646A1 FR 7523269 A FR7523269 A FR 7523269A FR 7523269 A FR7523269 A FR 7523269A FR 2318646 A1 FR2318646 A1 FR 2318646A1
Authority
FR
France
Prior art keywords
hydroxy
contg
dioxolane
dione
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7523269A
Other languages
French (fr)
Other versions
FR2318646B1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ILE DE FRANCE ETUDES SCIENTIFIQU
Original Assignee
ILE DE FRANCE ETUDES SCIENTIFIQU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ILE DE FRANCE ETUDES SCIENTIFIQU filed Critical ILE DE FRANCE ETUDES SCIENTIFIQU
Priority to FR7523269A priority Critical patent/FR2318646A1/en
Publication of FR2318646A1 publication Critical patent/FR2318646A1/en
Application granted granted Critical
Publication of FR2318646B1 publication Critical patent/FR2318646B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16

Abstract

The anaesthetic comprises 3 alpha-hydroxy-5 alpha-pregnane 11,20-dione (I) dissolved in 2,2-dimethyl-4-hydroxymethyl 1,3-dioxolane (Sol ketal RTM) (II). Advantages are rapid onset of action, and freedom from side effects. (I) is insoluble in water, but is sufficiently soluble in (II) to allow aq. preparations, e.g. contg. physiological serum or glucose, to be prepd. A typical compsn. contains 50 mg (I), 5 mg trihydroxymethyl aminomethane, 0.1 ml benzyl alcohol, 2.5 ml (II) and water for injection to 5 ml.
FR7523269A 1975-07-25 1975-07-25 Intravenous or perfusion anaesthetic - contg. a soln. of hydroxy pregnane dione in (2,2)-dimethyl-(4)-hydroxy-methyl-(1,3)-dioxolane Granted FR2318646A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7523269A FR2318646A1 (en) 1975-07-25 1975-07-25 Intravenous or perfusion anaesthetic - contg. a soln. of hydroxy pregnane dione in (2,2)-dimethyl-(4)-hydroxy-methyl-(1,3)-dioxolane

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7523269A FR2318646A1 (en) 1975-07-25 1975-07-25 Intravenous or perfusion anaesthetic - contg. a soln. of hydroxy pregnane dione in (2,2)-dimethyl-(4)-hydroxy-methyl-(1,3)-dioxolane

Publications (2)

Publication Number Publication Date
FR2318646A1 true FR2318646A1 (en) 1977-02-18
FR2318646B1 FR2318646B1 (en) 1978-10-06

Family

ID=9158363

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7523269A Granted FR2318646A1 (en) 1975-07-25 1975-07-25 Intravenous or perfusion anaesthetic - contg. a soln. of hydroxy pregnane dione in (2,2)-dimethyl-(4)-hydroxy-methyl-(1,3)-dioxolane

Country Status (1)

Country Link
FR (1) FR2318646A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997007807A1 (en) * 1995-08-23 1997-03-06 Colin Stanley Goodchild New use of pregnane-diones as analgesic agents
US6787530B1 (en) 1996-08-23 2004-09-07 Monash University Use of pregnane-diones as analgesic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NEANT *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997007807A1 (en) * 1995-08-23 1997-03-06 Colin Stanley Goodchild New use of pregnane-diones as analgesic agents
US6787530B1 (en) 1996-08-23 2004-09-07 Monash University Use of pregnane-diones as analgesic agents

Also Published As

Publication number Publication date
FR2318646B1 (en) 1978-10-06

Similar Documents

Publication Publication Date Title
Ginsburg Placental drug transfer
Bedwani et al. Enhanced inactivation of prostaglandin E2 by the rabbit lung during pregnancy or progesterone treatment.
EP0363886A3 (en) Blood perfusion system and tube means used therein
FI894423A (en) COMPOSITION OVER FARING FOERHINDRING AV BEFRUKTNING OCH KONTROLL AV BROESTCANCER.
BEDFORD et al. Studies on the biological disposition of griseofulvin, an oral antifungal agent
Yaffe Some aspects of perinatal pharmacology
Nugent et al. A comparative study of the metabolism of hydrocortisone and prednisolone
FR2318646A1 (en) Intravenous or perfusion anaesthetic - contg. a soln. of hydroxy pregnane dione in (2,2)-dimethyl-(4)-hydroxy-methyl-(1,3)-dioxolane
GB1495289A (en) Pharmaceutically active proteinaceous compounds
Llorach et al. Decreased vascular reactions to permeability factors in experimental diabetes.
Archer et al. Bradykinin and eosinophils
GB1355961A (en) Preparation of immunosuppressive antilymphocytic serum
Corrin et al. Fine structure of an oat cell carcinoma of the lung associated with ectopic ACTH syndrome
Musey et al. Estriol metabolism in the baboon: Analysis of urinary and biliary metabolites
Powell et al. Metronidazole combined with diloxanide furoate in amoebic liver abscess
Lucas et al. Identification and purification of immunosuppressive activity in the urine of rats and a human patient treated with niridazole
GB1505879A (en) Acylated orgotein
SU850082A1 (en) Method of treating chronic eczema
Estevez et al. Enhancement of stimulant activity in rats chronically treated with cocaine.
Müller et al. Significance of Australia antigen in patients after kidney transplantation
Pinter et al. Peritubular capillary permeability of albumin in saline and water diuresis
Ozeki et al. The effects of hydrocortisone and glycyrrhizine on the enzyme releases of arylsulfatase and hyaluronidase from lysosomes of liver
FR2226162A1 (en) Oligosaccharide sulphuric acid ester - for treatment of arteriosclerosis
Long et al. Experimental detection of left-to-right circulatory shunts with injections of krypton85
Truelove Treatment of ulcerative colitis with local hydrocortisone

Legal Events

Date Code Title Description
ST Notification of lapse